🇺🇸 FDA
Patent

US 11034739

Ligand-guided phagocytosis based therapy for treatment of Alzheimer's disease and other neurodegenerative diseases

granted A61KA61K38/00A61P

Quick answer

US patent 11034739 (Ligand-guided phagocytosis based therapy for treatment of Alzheimer's disease and other neurodegenerative diseases) held by The Board of Regents of the Nevada System of Higher Education on Behalf of the University of Nevada expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the Nevada System of Higher Education on Behalf of the University of Nevada
Grant date
Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K38/00, A61P, A61P25/28